Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-methyl-4-phenylpyridinium (MPP+) is a synthetic, cationic pyridinium compound that acts as a potent, selective neurotoxin for dopaminergic neurons and is most widely recognized as the active metabolite of MPTP, a compound that causes Parkinsonian pathology in animal models and humans. It achieves its neurotoxic effects through uptake by the dopamine transporter into neurons where it inhibits mitochondrial complex I, leading to oxidative phosphorylation inhibition, ATP depletion, production of reactive oxygen species, and dopaminergic cell death. This selectivity and the induction of Parkinson-like symptoms have made MPP+ a central tool in research on Parkinson's disease mechanisms. MPP+ has also been used historically as a herbicide (as cyperquat), though this use has been discontinued due to toxicity concerns[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-methyl-4-phenylpyridinium.